Analysis of the risk of transmitting bovine spongiform encephalopathy through bone grafts derived from bovine bone
Source abstract
Abstract
Bone substitutes of bovine origin are widely used for treatment of bone defects in dental and orthopedic surgery. Due to the occurrence of BSE and the new variant of Creutzfeldt Jakob Disease risks of transmitting diseases through the use of such materials need to be carefully evaluated. Risk analysis can either be based on theoretical assessments or experimental evidence. Here we present a comparative study on two bovine bone substitutes (Bio-Oss and Osteograf/N) which is based on theoretical values. Furthermore, for one of these materials, i.e. Bio-Oss, the prion inactivation capacity of one of the production steps was experimentally evaluated. Theoretical and experimental data indicate that the use of these materials does not carry a risk of transmitting BSE to patients.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Prion Diseases and Protein Misfolding · Trace Elements in Health
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. Preparation of a biphasic porous bioceramic by heating bovine cancellous bone with Na2P2O7×H2O addition10.1016/S0142-9612(98)00193-8 ↗
2. Characterization of xenogenic bone material
3. “Friendly fire” in medicine10.1016/0140-6736(92)92431-E ↗
4. A new variant of Creutzfeldt-Jakob disease in the UK10.1016/S0140-6736(96)91412-9 ↗
5. Bundesgesundheitsamt. Bekanntmachung der Sicherheitsanforderungen an Arzneimittel aus Körperbestandteilen von Rind, Schaf oder Ziege zur Vemeidung des Risikos einer Übertragung von BSE bzw. Scrapie. Bundesanzeiger 1994;40:1851–55.
6. Bundesgesundheitsamt. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln. Bundesanzeiger 1996;67:4158–62.
7. Validation of a Western immunoblotting procedure for bovine PrPSc detection and its use as a rapid surveillance method for the diagnosis of bovine spongiform encephalopathy (BSE)10.1007/s004010051106 ↗
8. Healing around implants in bone defects treated with Bio-Oss®10.1034/j.1600-0501.1997.080206.x ↗
9. The effect of a deproteinized bovine bone mineral on bone regeneration around titanium dental implants10.1034/j.1600-0501.1998.090302.x ↗
10. Maxillary sinus augmentation using different grafting materials and dental implants in monkeys
11. Risk assessment of bovine spongiform encephalopathy transmission through bone graft material derived from bovine bone used for dental applications10.1902/jop.1999.70.9.1053 ↗
12. Protein measurement with the folin phenol reagent10.1016/S0021-9258(19)52451-6 ↗
13. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline10.1021/ac60205a053 ↗
14. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie10.1007/BF01310794 ↗
15. Conditions for the chemical and physical inactivation of the K
16. Comparative analysis of scrapie agent inactivation methods10.1016/0166-0934(93)90126-C ↗
17. Effect of heat inactivation and freezing on fatty acid composition of plasma and red blood cells10.1016/0952-3278(92)90240-J ↗
18. Prions10.1073/pnas.95.23.13363 ↗
19. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie10.1099/0022-1317-77-8-1925 ↗
20. A protease-resistant protein is a structural component of the scrapie prion10.1016/0092-8674(83)90207-6 ↗
21. A cellular gene encodes scrapie PrP 27–30 protein10.1016/0092-8674(85)90333-2 ↗
22. Will RG. The transmission of prions to humans. Acta Paediatr 1999;(Suppl)88:28–32.10.1111/j.1651-2227.1999.tb14400.x ↗
23. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans10.1073/pnas.96.26.15137 ↗
24. Risk of transmission of BSE via drugs of bovine origin10.1016/S0140-6736(05)76082-7 ↗
25. Inactivation of transmissible degenerative encephalopathy agents10.1053/tvjl.1999.0406 ↗
26. Inactivation of prions by physical and chemical means10.1016/S0195-6701(99)90067-1 ↗
27. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE)
28. Risk of transmission of agents associated with Creutzfeldt-Jakob disease and bovine spongiform encephalopathy10.1097/00006534-199904040-00041 ↗